Log in to search using one of your social media accounts:

 

Colon cancer cells use mysterious RNA strands to avoid cell death
(Case Western Reserve University) Researchers from Case Western Reserve University School of Medicine have discovered how unusually long strands of RNA help colon cancer cells avoid death, allowing unregulated growth. Unlike other RNAs, the intriguing strands do not appear to encode proteins and are termed 'long non-coding RNAs' or 'lincRNAs.'A new study showed some lincRNAs could be targeted by drug developers to halt colon cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

Reducing cholesterol could enhance T-cell cancer immunotherapy
(Cleveland Clinic) Cleveland Clinic researchers have demonstrated for the first time that lowering blood cholesterol levels could enhance the success of a specific type of T-cell immunotherapy in fighting cancer. The team, led by Qing Yi, M.D., Ph.D., of Cleveland Clinic Lerner Research Institute studied T-cell transfer, which has shown great success in recent years. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

Cellular valve structure opens up potential novel therapies
(University of Zurich) Biochemists at the University of Zurich have determined the detailed structure of a volume-regulated chloride channel. This cellular valve is activated in response to swelling to prevent the cell from bursting. The protein also plays an important role in the uptake of chemotherapeutics and the release of neurotransmitters after a stroke. The controlled regulation of its activity thus opens up a promising strategy for novel therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

NIH, Northwestern scientists develop potential new approach to stop cancer metastasis
(NIH/National Center for Advancing Translational Sciences (NCATS)) Researchers have identified a compound that blocks the spread of pancreatic and other cancers in various animal models. When cancer spreads from one part of the body to another in a process called metastasis, it can eventually grow beyond the reach of effective therapies. Now, there is a new plan of attack against this deadly process, thanks to scientists at the National Institutes of Health, Northwestern University and their collaborative research partners. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

St. Jude named the WHO's first Collaborating Centre for Childhood Cancer
(St. Jude Children's Research Hospital) With the designation, St. Jude Children's Research Hospital will support efforts to improve detection and treatment of childhood cancer around the globe (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

Damon Runyon Cancer Research Foundation announces five new Physician-Scientist Training Awards
(Damon Runyon Cancer Research Foundation) To help increase the number of physician-scientists, the Damon Runyon Cancer Research Foundation has created the new Damon Runyon Physician-Scientist Training Award, which provides physicians who have earned an MD degree and completed clinical specialty fellowship training the opportunity to gain the research experience they need to become leaders in translational and clinical research. Damon Runyon announced that five scientists with novel approaches to fighting cancer have been named the 2018 recipients of the award. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

Mayo discovery means individualized ovarian, brain cancer therapies
(Mayo Clinic) Mayo Clinic researchers have discovered that a molecular communication pathway -- thought to be defective in cancer -- is a key player in determining the effectiveness of measles virus oncolytic cancer treatment in ovarian and aggressive brain cancers. This discovery enabled researchers to develop an algorithm to predict treatment effectiveness in individual patients. The findings appear in the Journal of the National Cancer Institute. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

Under certain conditions, bacterial signals set the stage for leukemia
(University of Chicago Medical Center) A new study by researchers from the University of Chicago Medicine shows that bacterial signals are crucial to the development of a precursor condition to leukemia, which can be induced by disrupting the intestinal barrier or by introducing a bacterial infection. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

A 'dirty bomb' battles cancer metastasis
(Northwestern University) Scientists have developed a new compound that inhibits the spread of cancer cells, which is what makes the disease so lethal. The compound, metarrestin, significantly reduced metastasis by human prostate, pancreatic and breast cancer transplanted into mice. Mice treated with it had fewer metastatic tumors and lived longer than mice that did not receive treatment. Metarrestin is being submitted to the FDA as an investigational drug. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

Cell type switch helps colon cancer evade treatment, study suggests
(Rockefeller University Press) Researchers in Germany have discovered that colon cancers are often resistant to existing drug treatments because they are composed of two different cell types that can replace each other when one cell type is killed. The study, which will be published May 16 in the Journal of Experimental Medicine, suggests that combination therapies targeting both cell types at once may be more effective at treating colorectal cancer, the third highest cause of cancer-related death in the United States. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

Queens Medical Associates to Hold Inaugural Clinical Trials Day on May...
Leading oncology and hematology practice educates public on importance of clinical trials, patient opportunities and advances in cancer treatment(PRWeb May 16, 2018)Read the full story at http://www.prweb.com/releases/2018/05/prweb15492065.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 16, 2018 Category: Pharmaceuticals Source Type: news

Colon Polyp Type May Be Key to Cancer Risk
(Source: Cancercompass News: Colorectal Cancer)
Source: Cancercompass News: Colorectal Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

Stunned scientists find BLUEBERRIES are better at destroying cancer cells than conventional radiation therapy alone
(Natural News) Cervical cancer strikes close to 13,000 women each year, claiming over 4,200 lives. Traditional treatment options include surgery to remove the affected tissue, radiation therapy using high energy x-rays to destroy cancer cells, chemotherapy drugs to destroy the affected cells (although healthy cells are killed too), or a combination thereof. However, these treatments... (Source: NaturalNews.com)
Source: NaturalNews.com - May 15, 2018 Category: Consumer Health News Source Type: news

Open records request reveals shocking e-mail from Kraft scientist claiming the "IARC is killing us!"
(Natural News) If the top cancer research agency in the world links one of your products to cancer, what should you do? The responsible thing would be to pull the product from the market and try to get to the bottom of the situation. If you feel they’re wrong, the most obvious course of action... (Source: NaturalNews.com)
Source: NaturalNews.com - May 15, 2018 Category: Consumer Health News Source Type: news

Iowa Man's Glyphosate Cancer Case Against Monsanto Sent To Roundup MDL
WASHINGTON, D.C. - The Judicial Panel on Multidistrict Litigation (JPMDL) on May 10 transferred to the multidistrict litigation for Roundup products liability litigation a case in which an Iowa man contends that he developed T-cell lymphoma as a result of exposure to glyphosate and other chemicals in the herbicide Roundup (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - May 15, 2018 Category: Medical Law Source Type: news

Texas Panel Reverses $6.98M Benzene Ruling, Says Causation 'Legally Insufficient'
DALLAS - A Texas appellate panel on May 8 reversed a trial court judgment of $6,985,535.25 and rendered a take-nothing judgment in favor of E.I. DuPont de Nemours and Co. after the panel determined that the evidence of causation regarding the company's liability for a man's cancer diagnosis related to benzene exposure was "legally insufficient" (E.I. DuPont de Nemours& Company v. Virgil Hood, et al., No. 05-16-00609-CV, Texas. App., 5th Dist.; 2018 Tex. App. LEXIS 3228). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - May 15, 2018 Category: Medical Law Source Type: news

Residents Sue Remediation Company For Falsifying Soil Samples From Superfund Site
SAN FRANCISCO - One hundred forty-nine residents who live near a Superfund site in San Francisco sued an environmental remediation company in California state court May 1, claiming that the company falsified soil samples during its alleged cleanup of the property and that its failure to fully complete the work it was paid $1.1 billion to do has led to higher rates of breast and cervical cancer and asthma (Bayview Hunters Point Residents, et al. v. Tetra Tech Inc., et al., No. CGC-18-566188, Calif. Super., San Francisco Co.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - May 15, 2018 Category: Medical Law Source Type: news

More men with low-risk prostate cancer are forgoing aggressive treatment
American doctors are successfully persuading increasing numbers of men with low-risk prostate cancer to reject immediate surgery and radiation in favor of surveillance, a trend that is sparing men's sexual health without increasing their risk of death. The latest evidence that more men are postponing aggressive therapy unless their symptoms worsen came in a large […]Related:Ebola has infected dozens so far in Congo, killing 19, WHO saysTroubling link found between pollution exposure in pregnancy, high blood pressure in childrenFor six decades, ‘the man with the golden arm’ donated blood — and saved...
Source: Washington Post: To Your Health - May 15, 2018 Category: Consumer Health News Source Type: news

Colon Polyp Type May Be Key to Cancer Risk
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 15, 2018 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Preventive Medicine, News, Source Type: news

MRI-Targeted Biopsy Prevails in Prostate Cancer
(MedPage Today) -- More significant, fewer insignificant cancers versus TRUS (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 15, 2018 Category: Hematology Source Type: news

Only Advanced Adenomas Confer Colorectal Cancer Risk
(MedPage Today) -- Risk with non-advanced lesions no greater than with no lesions at all (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - May 15, 2018 Category: Gastroenterology Source Type: news

Baby bibs, blankets contain toxins Canada banned in other products: report
Baby bibs, mats and blankets tested by scientists with NAFTA's environmental arm contain toxic chemicals linked to higher rates of cancer, infertility and suppressed immune systems — substances already banned from most other products in Canada. (Source: CBC | Health)
Source: CBC | Health - May 15, 2018 Category: Consumer Health News Tags: News/Politics Source Type: news

More men with low-risk prostate cancer are forgoing aggressive treatment, new study suggests
American doctors are successfully persuading increasing numbers of men with low-risk prostate cancer to reject immediate surgery and radiation in favor of surveillance, a trend that is sparing men's sexual health without increasing their risk of death. The latest evidence of the long-term trend came in a large study published Tuesday that involved more than […]Related:Ebola has infected dozens so far in Congo, killing 19, WHO saysTroubling link found between pollution exposure in pregnancy, high blood pressure in childrenFor six decades, ‘the man with the golden arm’ donated blood — and saved 2.4 m...
Source: Washington Post: To Your Health - May 15, 2018 Category: Consumer Health News Source Type: news

Bursectomy Does Not Improve Survival in Resectable Gastric Cancer Bursectomy Does Not Improve Survival in Resectable Gastric Cancer
In patients with resectable gastric cancer, bursectomy does not offer a survival advantage over the less radical omentectomy, researchers from Japan report.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 15, 2018 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Survival With Cervical Cancer Similar After Trachelectomy, Hysterectomy Survival With Cervical Cancer Similar After Trachelectomy, Hysterectomy
Trachelectomy to preserve fertility is being performed in a growing number of cervical cancer patients, especially those younger than 30, according to new findings.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 15, 2018 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Takeda Sees Lower Annual Profit, Generics to Erode Cancer Drug Sales Takeda Sees Lower Annual Profit, Generics to Erode Cancer Drug Sales
Japan's Takeda Pharmaceutical Co Ltd on Monday forecast a 17 percent drop in operating profit for the year through March 2019 as blood cancer drug Velcade (bortezomib) looks set to face generic competition in the United States.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2018 Category: Consumer Health News Tags: Pharmacist News Source Type: news

Improving Adherence to Endocrine Therapy in Women With HR-Positive Breast Cancer
Here, we discuss how to improve adherence to endocrine therapy in women with HR-positive breast cancer, as well as the side effects and the reasons for discontinuation. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Charles L. Shapiro, MD Julia P. Brockway, MD Tags: Breast Cancer Oncology Journal Source Type: news

Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors
A 65-year-old man presented with locally advanced, high-risk prostate cancer. His medical history was remarkable for type 2 diabetes mellitus, and he was an active smoker with a 27 pack-year history. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Francisco J. Castro-Alonso, MD Guillermo Rosales-Sotomayor Jennifer Dominguez-Pineda, MD Mar ía T. Bourlon, MD, MS Thomas W. Flaig, MD Tags: Genitourinary Cancers Oncology Journal Prostate Cancer Source Type: news

Robert Chapkin on Relationships Between the Gut Microbiome, Diet, and Colorectal Cancer
In this Q&A, we discuss the research into the relationships between gut microbiota, diet, and colorectal cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Robert S. Chapkin, MSc, PhD Tags: Colorectal Cancer Gastrointestinal Cancer Oncology Journal Source Type: news

Implications of Mutation Profiling in Myeloid Malignancies —PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies
In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Douglas Tremblay, MD John O. Mascarenhas, MD Kelsey Sokol, MD Raajit Rampal, MD Sheena Bhalla, MD Tags: Hematologic Malignancies Myeloproliferative Neoplasms Oncology Journal Review Article Source Type: news

Medic Vision wins FDA nod for MRI software
Image reconstruction software developer Medic Vision Imaging Solutions has...Read more on AuntMinnie.comRelated Reading: Medic Vision awarded dose patent RadNet acquires equity stake in Medic Vision Medic Vision points to new ACR FAQ on Smart Dose Radiology Oncology to sell Medic Vision CT software Philips taps Medic Vision's SafeCT for XR-29 compliance (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 15, 2018 Category: Radiology Source Type: news

Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
In this review, we highlight prospective data on checkpoint inhibition alone and in combination, discuss data regarding the efficacy and toxicity of combination therapy, and identify clinical scenarios that may favor treatment with combination therapy. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Allison Betof Warner, MD, PhD Michael A. Postow, MD Tags: Melanoma Oncology Journal Review Article Source Type: news

More men with low-risk prostate cancer are rejecting aggressive treatment, new study suggests
A sea change is occurring among men with low-risk prostate cancer: Increasing numbers are avoiding immediate surgery or radiation and are opting instead for close monitoring of the disease to see whether it worsens. The shift is sharply reducing unnecessary treatment that can cause serious side effects including incontinence and sexual problems, experts say, without […]Related:Ebola has infected dozens so far in Congo, killing 19, WHO saysTroubling link found between pollution exposure in pregnancy, high blood pressure in childrenFor six decades, ‘the man with the golden arm’ donated blood — and sa...
Source: Washington Post: To Your Health - May 15, 2018 Category: Consumer Health News Source Type: news

Egg farm responsible for salmonella outbreak had ‘unacceptable rodent activity,’ FDA report says
A North Carolina egg farm that authorities say is responsible for an outbreak of salmonella illness that has sickened several people in nine states has had a heavy rodent infestation and failed to take actions to reverse it, according to an inspection report. Dozens of rodents, some alive and some dead, were found inside Rose Acre Farms’ […]Related:More men with low-risk prostate cancer are rejecting aggressive treatment, new study suggestsEbola has infected dozens so far in Congo, killing 19, WHO saysTroubling link found between pollution exposure in pregnancy, high blood pressure in children (Sourc...
Source: Washington Post: To Your Health - May 15, 2018 Category: Consumer Health News Source Type: news

Md. biotech firm nears market with two drugs that could be safer for cancer patients
The CEO said his company aims to make cancer therapies that "eliminate the collateral damage" caused by other drugs on the market. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 15, 2018 Category: American Health Authors: Morgan Eichensehr Source Type: news

Mathematical method could automatize, enhance breast cancer diagnosis
Using mathematical models, researchers are developing algorithms and software that could automatize and enhance breast cancer diagnosis. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 15, 2018 Category: Consumer Health News Source Type: news

COUNTERPOINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer
Abiraterone has become the first-choice treatment for men with metastatic prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Robert J. Jones, MBChB, PhD Tags: Genitourinary Cancers Oncology Journal Prostate Cancer Source Type: news

Md. biotech firm nears market with two drugs that could be safer for cancer patients
Peter D. Suzdak, CEO of Rexahn Pharmaceuticals, said his company aims to make cancer therapies that "eliminate the collateral damage" caused by other drugs on the market. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 15, 2018 Category: American Health Authors: Morgan Eichensehr Source Type: news

POINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer
Chemotherapy is the best option for the initial management of metastatic prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Mario A. Eisenberger, MD Pedro Isaacsson Velho, MD Tags: Genitourinary Cancers Oncology Journal Prostate Cancer Source Type: news

CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor –Positive Advanced Breast Cancer?
Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Maria Raquel Nunes, MD Mirat Shah, MD Vered Stearns, MD Tags: Breast Cancer Oncology Journal Review Article Source Type: news

Novel Algorithm Can Help Create 3 - D Human Nose Prosthesis
High overall similarity between 3 - D models and photographs of volunteers'noses (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 15, 2018 Category: Cancer & Oncology Tags: Oncology, ENT, Surgery, Journal, Source Type: news

Marketing and Opioid Scripts; CBT and Migraine; Cancer Diagnosis and Stroke
(MedPage Today) -- News and commentary from the world of neurology and neuroscience (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - May 15, 2018 Category: Psychiatry Source Type: news

Colon Polyp Type May Be Key to Cancer Risk
TUESDAY, May 15, 2018 -- The type of colon polyp that's spotted during a colonoscopy may help predict the likelihood of colon cancer, new research shows. These polyps -- also called adenomas -- can be labeled advanced or non-advanced, explained... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 15, 2018 Category: General Medicine Source Type: news

Medical News Today: Colorectal cancer: Some cells are 'born to be bad'
A small study finds that genetic signatures for cell migration and metastasis are already present in early malignant — but not benign — colorectal tumors. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 15, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

6 Ways to Make Your Coffee Even Healthier
This article originally appeared on Health.com (Source: TIME: Health)
Source: TIME: Health - May 15, 2018 Category: Consumer Health News Authors: Cynthia Sass / Health.com Tags: Uncategorized Diet/Nutrition healthytime onetime Source Type: news

Florida and Minnesota immunotherapy cos. to merge, move HQ to Houston
TapImmune Inc. (Nasdaq: TPIV), a Jacksonville, Florida-based developer of cancer fighting immunotherapies, is merging with Marker Therapeutics Inc., a Minnesota-based developer of similar T-cell therapies. The newly formed company will be based in Houston, due to a strategic alliance with Baylor College of Medicine. TapImmune and Marker will each own half of the company, though the deal is still subject to the approval of TapImmune's stockholders. Marker is privately held. The combined company will… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 15, 2018 Category: Biotechnology Authors: Will Robinson Source Type: news

PFS Is a Shortcut, Not a Destination PFS Is a Shortcut, Not a Destination
Oncologists need to remember that PFS is a surrogate for the most important endpoint--how long our patients live, argues H. Jack West, MD.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 15, 2018 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

Study Evaluates Systemic Chemotherapy on Peritoneal Mesothelioma
Systemic chemotherapy, either before or after cytoreductive surgery, provided no improvement in long-term survival for patients with peritoneal mesothelioma, according to a recent study. The addition of systemic chemotherapy improved survival at the one-year mark, but there were no benefits at the two-, three- or five-year checkpoints. Systemic chemotherapy uses anti-cancer drugs that are injected into a vein or given by mouth. The median survival of surgical patients who received systemic chemotherapy did not improve, either. “We know surgery is the best option, and if the surgery is successful, chemotherapy may not...
Source: Asbestos and Mesothelioma News - May 15, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

WHRY funds study to enable early detection, treatment of ovarian cancer
Led by Ryan Jensen, Women ’s Health Research at Yale is aiming to understand the drivers that lead to ovarian tumors in women with certain gene mutations. (Source: Yale Science and Health News)
Source: Yale Science and Health News - May 15, 2018 Category: Universities & Medical Training Source Type: news

Merger takes Jacksonville immunotherapy company to Houston
TapImmune Inc. (Nasdaq: TPIV), the Jacksonville-based developer of cancer fighting immunotherapies, is merging with Marker Therapeutics Inc., a Minnesota-based developer of similar T-cell therapies. The newly formed company will be based in Houston, due to a strategic alliance with the Baylor College of Medicine. TapImmune and Marker will each own half of the company, though the deal is still subject to the approval of TapImmune's stockholders. Marker is privately held. The combined company will… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 15, 2018 Category: Biotechnology Authors: Will Robinson Source Type: news